Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Clinical Immunology · OTULIN-related autoinflammatory syndrome

Understanding Your Child's ORAS Diagnosis

At a Glance

ORAS, also called otulipenia or AIPDS, is a very rare genetic autoinflammatory disease caused by OTULIN variants that can keep the innate immune system active. It often begins in infancy with recurrent fevers and panniculitis; genetic and immune evaluation guides diagnosis, care, and family counseling.

Receiving a diagnosis of a rare genetic condition is often a journey marked by profound uncertainty, especially when it occurs shortly after birth. For many parents, the path to a name like OTULIN-related autoinflammatory syndrome (ORAS) is paved with months of unexplained fevers and skin changes [1][2]. It is normal to feel a mix of relief that the “diagnostic odyssey” has ended, alongside deep anxiety or even grief about what the future holds [3][4].

What is ORAS?

This condition is known by several names, including otulipenia or autoinflammation, panniculitis, and dermatosis syndrome (AIPDS) [5]. Regardless of the name, it is an autoinflammatory disease, which means the innate immune system is essentially “stuck on” and produces spontaneous inflammation [2]. While this is a primary dysregulation and distinct from the autoantibody-driven mechanisms typical of many autoimmune diseases, it is critical to remember that infection still requires evaluation, as fevers are not always spontaneous.

ORAS is caused by changes (variants) in the OTULIN gene [5]. Most children with this condition inherit two copies of a non-working gene—one from each parent (autosomal recessive)—though rare cases involve a different genetic mechanism (dominant-negative) [5][6]. It is critical to understand that this is a genetic occurrence; it is not caused by anything you did during pregnancy or childhood [7]. Because recurrence risk depends on the exact inheritance mechanism, families are strongly encouraged to seek genetic counseling.

How ORAS Affects the Body

The condition typically appears very early in life, often in the neonatal period [1]. While every child is different, the “classic” presentation includes:

  • Recurrent Fevers: High temperatures that come and go, though an infection should never be ruled out [2].
  • Panniculitis: Painful, red, or purple nodules under the skin caused by inflammation of the fat layer [8].
  • Gastrointestinal Issues: Chronic diarrhea or signs of IBD-like intestinal inflammation have been reported in some patients [1][9].
  • Joint and Liver Involvement: Some children experience arthritis (joint swelling and pain), and progressive liver issues like steatotic liver disease have been reported, although their frequency and course are uncertain [1][9].

Distinguishing ORAS from APLAID

Because rare diseases often have overlapping symptoms, ORAS is sometimes confused with another condition called APLAID (PLCG2-associated antibody deficiency and immune dysregulation). While both involve early-onset inflammation, they are distinct diseases with overlapping phenotypes. The table below is not diagnostic; genetic and immunologic evaluation distinguishes them:

Feature ORAS (Otulipenia) APLAID
Genetic Cause OTULIN gene [5] PLCG2 gene [10]
Primary Skin Symptom Panniculitis (deep nodules) [8] Blistering or ulcerating rashes [11]
Immune System Overactive innate inflammation [12] Inflammation often alongside low antibodies/B-cells [13]
Infections Risk depends on disease and treatment [5] Frequent lung or sinus infections often reported [10]

The Science of the “Stuck Switch”

In a healthy body, a protein called OTULIN acts like a master switch that trims away specific molecular “tags” (called M1-linked ubiquitin chains) that tell the immune system to start an inflammatory response [12][2]. In ORAS, this switch is broken. These tags build up, leading to the constant activation of two major inflammatory pathways: NF-κB and TNF [12][14]. This dysregulation not only drives spontaneous inflammation but can also cause certain cells to die prematurely through abnormal TNF-induced cell death, contributing to the skin and gut issues seen in patients [2][15].

Understanding Rarity and Uncertainty

ORAS is an ultra-rare condition, with very few cases reported worldwide [2][5].

Because there are so few patients, research is still catching up. While doctors understand the “stuck switch” mechanism well and have published case reports showing success using TNF inhibitors to dampen the inflammation, the long-term prognosis—what life looks like for these children as they reach adulthood—is not yet fully known [12][5]. You are not just a parent; in the world of rare disease, you and your medical team are often pioneers contributing to the collective understanding of the condition [16].

Managing the Emotional Impact

The shift from being a parent to being an “expert caregiver” and “care coordinator” is exhausting [16]. It is common to feel a sense of hyper-vigilance, constantly scanning your child for the next flare-up [4].

  • Acknowledge the stress: Anxiety, frustration, and a sense of isolation are frequent among families with rare genetic diagnoses [7].
  • Seek specialized support: Genetic counseling can help you understand the risks for future children, while psychological support can provide tools for managing the ongoing uncertainty [17][18].
  • Focus on the present: Many families find that focusing on day-to-day management, rather than attempting to solve the mystery of the distant future, helps maintain a sense of control [19].

Common questions in this guide

What is ORAS, and what does otulipenia mean?
ORAS is a very rare genetic autoinflammatory disease caused by changes in the OTULIN gene. It can make the body’s innate immune system stay active, leading to inflammation that often begins in infancy with fever and panniculitis. Otulipenia and autoinflammation, panniculitis, and dermatosis syndrome are other names for the same condition.
What symptoms might a child with ORAS develop?
Children may have recurrent fevers and panniculitis, which causes painful red or purple lumps under the skin. Some also develop chronic diarrhea or intestine inflammation resembling inflammatory bowel disease, arthritis, or liver problems such as steatotic liver disease. Symptoms and severity vary between children.
How is an ORAS diagnosis confirmed?
Diagnosis is usually based on the child’s symptoms together with genetic testing for OTULIN variants and an immune evaluation. Most affected children have two non-working OTULIN copies, one inherited from each parent, although rare dominant-negative variants have also been reported. A genetic counselor can explain what the result means for relatives and future pregnancies.
How is ORAS different from APLAID?
ORAS is linked to OTULIN variants and commonly causes deep, inflamed nodules called panniculitis. APLAID is linked to PLCG2 variants and may involve blistering or ulcerating rashes, low antibody levels, or frequent infections. Genetic and immune testing—not symptoms alone—helps distinguish the two conditions.
Does every fever mean an ORAS flare?
No. Because children with ORAS can also develop infections, a fever should not automatically be assumed to be spontaneous inflammation or a flare. Follow the evaluation and treatment plan from your child’s healthcare team, especially when fever is new, severe, or accompanied by other concerning symptoms.
What treatments and monitoring might a child with ORAS need?
TNF inhibitors have helped reduce inflammation in some reported ORAS cases, but evidence is limited because the condition is extremely rare. Follow-up is individualized and may include an immunologist, gastroenterologist, and monitoring of inflammatory activity, liver health, and joints. Your child’s team also considers infection risk and response to treatment.

Get notified when new evidence is published on autoinflammation, panniculitis, and dermatosis syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (19)
  1. 1

    Compound heterozygous variants in OTULIN are associated with fulminant atypical late-onset ORAS.

    Zinngrebe J, Moepps B, Monecke T, et al.

    EMBO molecular medicine 2022; (14(3)):e14901 doi:10.15252/emmm.202114901.

    PMID: 35170849
  2. 2

    OTULIN deficiency in ORAS causes cell type-specific LUBAC degradation, dysregulated TNF signalling and cell death.

    Damgaard RB, Elliott PR, Swatek KN, et al.

    EMBO molecular medicine 2019; (11(3)) doi:10.15252/emmm.201809324.

    PMID: 30804083
  3. 3

    The expected utility and psychological impacts of exome sequencing results in the DDD-Africa study.

    Schnell S, Goliath Z, Shingwenyana B, et al.

    Journal of genetic counseling 2026; (35(3)):e70251 doi:10.1002/jgc4.70251.

    PMID: 42360085
  4. 4

    Evaluation of the parents' anxiety levels before and after the diagnosis of their child with a rare genetic disease: the necessity of psychological support.

    Kolemen AB, Akyuz E, Toprak A, et al.

    Orphanet journal of rare diseases 2021; (16(1)):402 doi:10.1186/s13023-021-02046-2.

    PMID: 34583726
  5. 5

    OTULIN-related conditions: Report of a new case and review of the literature using GenIA.

    Caballero-Oteyza A, Crisponi L, Peng XP, et al.

    Research square 2024; doi:10.21203/rs.3.rs-3950863/v2.

    PMID: 38712244
  6. 6

    Dominant negative OTULIN-related autoinflammatory syndrome.

    Davidson S, Shibata Y, Collard S, et al.

    The Journal of experimental medicine 2024; (221(6)) doi:10.1084/jem.20222171.

    PMID: 38630025
  7. 7

    The supportive care needs of parents with a child with a rare disease: results of an online survey.

    Pelentsov LJ, Fielder AL, Laws TA, Esterman AJ

    BMC family practice 2016; (17()):88 doi:10.1186/s12875-016-0488-x.

    PMID: 27439905
  8. 8

    New data in causes of autoinflammatory diseases.

    Kone-Paut I, Georgin-Laviallec S, Galeotti C, et al.

    Joint bone spine 2019; (86(5)):554-561 doi:10.1016/j.jbspin.2018.11.003.

    PMID: 30471422
  9. 9

    OTULIN protects the liver against cell death, inflammation, fibrosis, and cancer.

    Damgaard RB, Jolin HE, Allison MED, et al.

    Cell death and differentiation 2020; (27(5)):1457-1474 doi:10.1038/s41418-020-0532-1.

    PMID: 32231246
  10. 10

    Novel PLCG2 Mutation in a Patient With APLAID and Cutis Laxa.

    Neves JF, Doffinger R, Barcena-Morales G, et al.

    Frontiers in immunology 2018; (9()):2863 doi:10.3389/fimmu.2018.02863.

    PMID: 30619256
  11. 11

    Expanding the clinical features of autoinflammation and phospholipase Cγ2-associated antibody deficiency and immune dysregulation by description of a novel patient.

    Morán-Villaseñor E, Saez-de-Ocariz M, Torrelo A, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2019; (33(12)):2334-2339 doi:10.1111/jdv.15918.

    PMID: 31465591
  12. 12

    The Deubiquitinase OTULIN Is an Essential Negative Regulator of Inflammation and Autoimmunity.

    Damgaard RB, Walker JA, Marco-Casanova P, et al.

    Cell 2016; (166(5)):1215-1230.e20 doi:10.1016/j.cell.2016.07.019.

    PMID: 27523608
  13. 13

    Severe Autoinflammatory Manifestations and Antibody Deficiency Due to Novel Hypermorphic PLCG2 Mutations.

    Martín-Nalda A, Fortuny C, Rey L, et al.

    Journal of clinical immunology 2020; (40(7)):987-1000 doi:10.1007/s10875-020-00794-7.

    PMID: 32671674
  14. 14

    OTULIN protects the intestinal epithelium from apoptosis during inflammation and infection.

    Verboom L, Anderson CJ, Jans M, et al.

    Cell death & disease 2023; (14(8)):534 doi:10.1038/s41419-023-06058-7.

    PMID: 37598207
  15. 15

    OTULIN inhibits RIPK1-mediated keratinocyte necroptosis to prevent skin inflammation in mice.

    Schünke H, Göbel U, Dikic I, Pasparakis M

    Nature communications 2021; (12(1)):5912 doi:10.1038/s41467-021-25945-1.

    PMID: 34625557
  16. 16

    Alone in a Crowd? Parents of Children with Rare Diseases' Experiences of Navigating the Healthcare System.

    Baumbusch J, Mayer S, Sloan-Yip I

    Journal of genetic counseling 2018; doi:10.1007/s10897-018-0294-9.

    PMID: 30128673
  17. 17

    Exploring the experience of communication in healthcare settings with parents of children with a rare genetic condition: "It's the more negative ones that you remember".

    Burbury L, Ayres S, Boyle J, et al.

    Journal of genetic counseling 2025; (34(4)):e70102 doi:10.1002/jgc4.70102.

    PMID: 40831303
  18. 18

    Genetics follow up after rapid genomic sequencing in intensive care: current practices and recommendations for service delivery.

    Lynch F, Nisselle A, Stark Z, et al.

    European journal of human genetics : EJHG 2022; (30(11)):1276-1282 doi:10.1038/s41431-022-01168-w.

    PMID: 35953518
  19. 19

    How parents of children with ataxia-telangiectasia use dynamic coping to navigate cyclical uncertainty.

    Schiller J, Towne MC, Epstein R, et al.

    Journal of genetic counseling 2024; (33(2)):301-313 doi:10.1002/jgc4.1727.

    PMID: 37183503

This page is for informational purposes only and does not constitute medical advice about your child's ORAS diagnosis. Discuss fevers, infection concerns, genetic testing, and treatment decisions with your child's care team.